Observational studyDeutsches Arzteblatt international2026
Polypharmacy Among 200 000 Subjects of the Population-Based German National Cohort Study (NAKO), Aged 19-74: A Baseline Analysis.
Observational study in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolypharmacy is associated with adverse events, impaired quality of life, and increased mortality, but population-based studies that include both prescribed and over-the-counter (OTC) drugs are scarce.
methodsWe analyzed baseline data from the German National Cohort Study (NAKO), Germany's largest population-based cohort study (recruitment 2014-2019, subjects aged 19-74 at baseline). We determined the prevalence of polypharmacy (defined as the reported regular use of ≥5 prescribed or OTC drugs) and hyperpolypharmacy (≥10 drugs), stratified by sex and age. Determinants of polypharmacy were estimated with logistic regression.
resultsOut of 203 765 subjects (mean age 49.8 years, 50.4% female), polypharmacy was present in 6869 women (6.7%, 95% confidence interval [6.5%; 6.8%]) and 8126 men (8.0% [7.9%; 8.2%]), hyperpolypharmacy in 505 women (0.5% [0.45%; 0.54%]) and 722 men (0.7% [0.67%; 0.77%]). Both were more prevalent at older ages. Diabetes mellitus and chronic cardiovascular conditions were strong determinants of polypharmacy, and cardiovascular drugs were the most commonly reported type.
conclusionPolypharmacy was common in the NAKO, particularly in older subjects, men, and people with cardiovascular disease. The appropriateness of drug use could not be assessed in this study. Future studies should examine inappropriate polypharmacy and evaluate risk factors and deprescribing strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.